european journal of pharmaceutics and biopharmaceutics : official journal of arbeitsgemeinschaft fur pharmazeutische verfahrenstechnik ev

ejnmmi research

[1] Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.

[2] novel preclinical and radiopharmaceutical aspects of [68ga]ga-psma-hbed-cc: a new pet tracer for imaging of prostate cancer

[3] Are superior cervical sympathetic ganglia avid on whole body 68Ga-PSMA-11 PET/magnetic resonance?: a comprehensive morphologic and molecular assessment in patients with prostate cancer.

[4] Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour.

[5] False-Positive Pancreatic Uptake Detected on 68Ga-PSMA PET/CT: A Priority Changing Incidental Finding While Assessing the Need for a Prostate Biopsy.

[6] Corrigendum to ‘Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA’ (Bioorganic & Medicinal Chemistry Letters (2019) 29(10) (1246–1255), (S0960894X19300617), (10.1016/j.bmcl.2019.01.040))

[7] Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA

[8] A feasibility study of 'The StepSmart Challenge' to promote physical activity in adolescents.

[9] Isoporous Membranes from Novel Polystyrene--poly(4-vinylpyridine)--poly(solketal methacrylate) (PS--P4VP--PSMA) Triblock Terpolymers and Their Post-Modification.

[10] Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer.

[11] Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml.

[12] a comparison of the biological features of prostate cancer with (psa+, psma+) profile according to rkip

[13] novel preclinical and radiopharmaceutical aspects of [68ga]ga-psma-hbed-cc: a new pet tracer for imaging of prostate cancer

[14] imaging tumour thrombus of clear cell renal cell carcinoma: fdg pet or psma pet? direct in vivo comparison of two technologies

[15] diagnosis of prostate cancer using anti-psma aptamer a10-3.2-oriented lipid nanobubbles

[16] enhancement of psma-directed car adoptive immunotherapy by pd-1/pd-l1 blockade

[17] Diagnostic accuracy of Ga-PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen.

[18] Antiprostate-specific membrane antigen (PSMA)-based radioimmunotherapy: A combined analysis of radiolabeled-J591 studies.

[19] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer